Sarah Sheibani, MD
Gastroenterology · Los Angeles, CANPI 1891975967
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,225 of the $17,630 with a category attached, or 86.4%. Johnson & Johnson accounts for 93.0% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $16,847, more than ten times the $238 reported in 2022.
Across 36 payments — averaging $489.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$16K
- AbbVie$732
- E.r. Squibb & Sons, L.L.C.$146
- Aimmune Therapeutics, Inc.$125
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$94
- Takeda Pharmaceuticals U.S.A., Inc.$67
- plus $64 from 2 others
Across 28 payments — averaging $4806.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$90K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Janssen Research & Development, LLC$21K
What the payments were for
- Speaking & faculty fees$15,22586%
- Travel & lodging$5843%
- Food & beverage$1,82110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $16,402 |
| AbbVie | 15 | $732 |
| E.r. Squibb & Sons, L.L.C. | 1 | $146 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Celltrion USA Inc. | 1 | $39 |
| Bristol Myers Squibb | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,630 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 36 | $907,411 |
| GattexTeduglutide | 12 | $547,412 |
| CreonLipase/Protease/Amylase | 14 | $36,513 |
| LinzessLinaclotide | 31 | $17,958 |
| Colestipol Hcl | 20 | $1,199 |
| Sodium Chloride0.9 % Sodium Chloride | 22 | $512 |
| Pantoprazole Sodium | 23 | $221 |
| Omeprazole | 22 | $201 |
| Famotidine | 11 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $16,402 | $907,41136 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $67 | $547,41212 claims |
| AbbVieCreon, Linzess | $732 | $54,47245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Los Angeles
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$1.9M
- Sadeea AbbasiLos Angeles$556K
- Gil MelmedLos Angeles$467K
- Venkataraman MuthusamyLos Angeles$297K
- Caroline HwangLos Angeles$279K
- Adarsh ThakerLos Angeles$241K
- Andres YarurLos Angeles$218K
- Joseph PisegnaLos Angeles$210K
- Steven-Huy HanLos Angeles$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.